[HTML][HTML] Parkinson disease-associated cognitive impairment
Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …
Epidemiology of Parkinson's disease
A Elbaz, L Carcaillon, S Kab, F Moisan - Revue neurologique, 2016 - Elsevier
Parkinson's disease (PD) is the second most common neurodegenerative disease after
Alzheimer's. PD is considered a multifactorial disorder that results, in most cases, from the …
Alzheimer's. PD is considered a multifactorial disorder that results, in most cases, from the …
Incidence of Parkinson disease in North America
Parkinson disease (PD) is the second most common age-related neurodegenerative
condition diagnosed in North America. We recently demonstrated, using multiple …
condition diagnosed in North America. We recently demonstrated, using multiple …
The current and projected economic burden of Parkinson's disease in the United States
SL Kowal, TM Dall, R Chakrabarti… - Movement …, 2013 - Wiley Online Library
Parkinson's disease (PD), following Alzheimer's disease, is the second‐most common
neurodegenerative disorder in the United States. A lack of treatment options for changing …
neurodegenerative disorder in the United States. A lack of treatment options for changing …
Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment
Dementia is one of the most common and important aspects of Parkinson's disease and has
consequences for patients and caregivers, and has health-related costs. Mild cognitive …
consequences for patients and caregivers, and has health-related costs. Mild cognitive …
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
D Weintraub, T Simuni, C Caspell‐Garcia… - Movement …, 2015 - Wiley Online Library
This study was undertaken to determine the prevalence and correlates of cognitive
impairment (CI) and neuropsychiatric symptoms (NPS) in early, untreated patients with …
impairment (CI) and neuropsychiatric symptoms (NPS) in early, untreated patients with …
[PDF][PDF] European physiotherapy guideline for Parkinson's disease
S Keus, M Munneke, M Graziano… - The Netherlands …, 2014 - parkinsonnet.nl
6 Guidelines((“guideline”[pt] OR “practice guideline”[pt] OR “health planning guidelines”[mh]
OR “consensus development conference”[pt] OR “consensus development conference …
OR “consensus development conference”[pt] OR “consensus development conference …
Manganese promotes the aggregation and prion-like cell-to-cell exosomal transmission of α-synuclein
The aggregation of α-synuclein (αSyn) is considered a key pathophysiological feature of
certain neurodegenerative disorders, collectively termed synucleinopathies. Given that a …
certain neurodegenerative disorders, collectively termed synucleinopathies. Given that a …
APOE genotype regulates pathology and disease progression in synucleinopathy
Apolipoprotein E (APOE) ε4 genotype is associated with increased risk of dementia in
Parkinson's disease (PD), but the mechanism is not clear, because patients often have a …
Parkinson's disease (PD), but the mechanism is not clear, because patients often have a …
Early predictors of mortality in parkinsonism and Parkinson disease: a population-based study
D Bäckström, G Granåsen, ME Domellöf, J Linder… - Neurology, 2018 - AAN Enterprises
Objective To examine mortality and associated risk factors, including possible effects of mild
cognitive impairment, imaging, and CSF abnormalities, in a community-based population …
cognitive impairment, imaging, and CSF abnormalities, in a community-based population …